Evidence map›Paper›PMID 42369709›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026

[Establish a Zebrafish Atherosclerosis Model Screening Platform to Evaluate the Therapeutic Effects of Qi-Regulating and Blood-Activating Prescriptions on Atherosclerosis].

Jiufeng Yin, Hui Wang, Haoyan Wang, Tong Jiang, Xinyi Zhang, Mingkai Li, Dan Zhang, Feng Zhao, Wenqing Yang

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiufeng Yin（ 250300）Institute of Innovation in Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.ORCID 0009-0004-5856-0999
Hui Wang（ 250300）Institute of Innovation in Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.
Haoyan Wang（ 250300）Institute of Innovation in Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.
Tong Jiang（ 250300）Institute of Innovation in Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.
Xinyi Zhang（ 250300）Institute of Innovation in Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.
Mingkai Li（ 250300）Institute of Innovation in Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.
Dan Zhang（ 250300）Institute of Innovation in Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.
Feng Zhao（ 250300）Institute of Innovation in Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.ORCID 0000-0002-0969-3697
Wenqing Yang（ 250300）Institute of Innovation in Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.ORCID 0000-0003-4622-7393

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To systematically identify traditional Chinese medicine (TCM) compound formulas with anti-atherosclerosis (AS) potential using a screening platform based on multi-strain Methods: Screening was conducted using a formula dictionary database, and compound formulas such as Dan Shen Fang, Shang Ni San, Jin Lingzi San, and Li Qi Hua Liang Tang were selected from 933 blood-activating and stasis-resolving formulas. Five strains of Results: Compared with the AS model group, compound Dan Shen Fang and Shang Ni San improved lipid accumulation in the vascular lumen, reduced total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, decreased oxidative stress response, inhibited the recruitment of neutrophils and macrophages, repaired vascular endothelial damage, improved blood flow velocity, and reduced the expression of inflammatory factors, thereby alleviating AS, with statistically significant differences. Jin Lingzi San and Li Qi Hua Liang Tang had limited effects on AS. Conclusion: This platform provides an efficient and targeted tool for the screening and research evaluation of anti-atherosclerosis TCM compound formulas, accelerates the research progress of anti-atherosclerosis TCM compound formulas, and lays a foundation for subsequent drug development and clinical application.

Indexed as

AtherosclerosisDisease Models, AnimalDrugs, Chinese HerbalAnimalsZebrafishDrugs, Chinese HerbalAtherosclerosisChinese medicine compound formulasDrug screeningZebrafish

Identifiers

PMID42369709
PMCPMC13303389

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.